D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion

NeuroReport

Volumn 10, Issue 15, 1999, Pages 3131-3136

  Menalled, Liliana B ^a   Dziewczapolski, Gustavo ^a   Garcia, Maria C ^a   Rubinstein, Marcelo ^b   Gershanik, Oscar S ^a  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b NONE

Author keywords

Antisense oligodeoxynucleotide; D3 dopamine receptor; Dopamine depleted rat; Islands of Calleja; Locomotor activity

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOPAMINE 3 RECEPTOR; ADRENERGIC RECEPTOR AFFECTING AGENT; APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRD3 PROTEIN, RAT; OLIGONUCLEOTIDE; RESERPINE;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE BRAIN LEVEL; FEMALE; LOCOMOTION; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SYNAPTIC TRANSMISSION; ANIMAL; AUTORADIOGRAPHY; BINDING SITE; DOWN REGULATION; DRUG EFFECT; METABOLISM; NUCLEIC ACID PROBE; OLFACTORY NERVOUS SYSTEM; PHYSIOLOGY; TIME; WISTAR RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTISENSE ELEMENTS (GENETICS); APOMORPHINE; AUTORADIOGRAPHY; BINDING SITES; DOPAMINE AGONISTS; DOWN-REGULATION; FEMALE; ISLANDS OF CALLEJA; LOCOMOTION; OLIGONUCLEOTIDES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RESERPINE; TIME FACTORS;

EID: 0032589958     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199910190-00002     Document Type: Article

References (32)

1. 1. Malmberg A, Jackson DM, Ericksson A and Mohell N. Mol Pharmacol 43, 749-754 (1993).
2. 2 Bouthenet NE, Souil E, Martres NW et al. Brain Res 564, 203-219 (1991).
3. 3. Diaz J, Lévesque D, Lammers CH et al. Neuroscience 65, 731-745 (1995).
4. 4. Sokoloff P, Giros B, Martres NW et al. Nature 347, 146-151 (1990).
5. 5. Landwehrmeyer B, Mengod G and Palacios JM. Eur J Neurosci 5, 145-153 (1993).
6. 6. Lejeune F and Milfan MJ. Eur J Pharmacol 275, R7-R9 (1995).
7. 7. Lepper JM, Sun BC, Martin LP and Creese Y. J Neurosci 17, 2519-2530 (1997).
8. 8. Meller E, Bohmaker K, Goldstein M and Basham DA. Eur J Pharmacol 249, R5-R6 (1993).
9. 9. Gobert A, Rivet JM, Audinot V et al. J Pharmacol Exp Ther 275, 899 913 (1995).
10. 10. Waters N, Svensson K, Haadsma-Svensson SR et al. J Neural Transm (GenSect) 94, 1119 (1993).
11. 11. Svensson K, Carlsson A and Waters N. J Neural Transm 95, 71-74 (1994).
12. 12. Sautel F, Grillon N, Sokoloff P et al. J Pharmacol Exp Ther 275, 1239-1246 (1995).
13. 13. Accili D, Fishburn CS, Drago J et al. Proc Natl Acad Sci USA 93, 1945-1949 (1996).
14. 14. Xu M, Koeltzow TE, Tirado Santiago G et al. Neuron 19, 837-848 (1997).
15. 15. Burris KD, Pacheco MA, Filtz TM et al. Neuropsychopharmacology 12, 335-345 (1995).
16. 16. Xu M, Koeltzow TE, Cooper DC et al. Synapse 31, 210-215 (1999).
17. 17. Boulay D, Depoortere R, Rostene W et al. Neuropharmacology 38, 555-565 (1999).
18. 18. Kelly MA, Rubinstein M, Phillips TJ et al. J Neurosci 18, 3470-3479 (1998).
19. 19. Banbury Conference on Genetic Background in Mice. Neuron 19, 755-759 (1997).
20. 20. Ekman A, Nissbrandt, Heilig M et al. Naunyn-Schmierdeberg's Arch Pharmacol 358, 342-350 (1998).
21. 21 Dziewczapolski G, Menalled LB, Garcia MC et al. Nouroreport 9, 1-5 (1998).
22. 22 Dziewczapolski G, Mora MA, Menalled LB et al. Naunyn-Schmiedeberg's Arch Pharmacol 355, 30-35 (1997).
23. 23. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986.
24. 24. Dziewczapolski G, Murer G, Agid Y et al. Neuroreport 8, 975-979 (1997).
25. 25. Heimer L and Wilson RD. The subcortical projections of the allocortex: similarities in the neural associations of the hippocampus, the piriform cortex and the neocortox, in: Golgi Centennial Symposium: Perspectives in Neurobiology. New York: Raven Press, 1975.
26. 26. Björklund A and Lindvall O, Dopamine-containing systems in the CNS. In: Handbook of Chemical Neuroanatomy, Vol. 2 Classical transmitters In the CNS. Amsterdam: Elsevier, 1984.
27. 27. Schwartz JC, Levesque D, Martres NW and Sokoloff P. Clin Neuropharmacol 16, 295-314 (1993).
28. 28. Fallon JH. Brain Res Bull 10, 775-793 (1983).
29. 29. Fallon JH, Loughlin SE and Ribak CE. J Comp Neurol 218, 91-120 (1983).
30. 30. Fallon JH, Riley JN, Sipe JC and More RY. J Comp Neurol 181, 375-396 (1978).
31. 31. Larson ER and Ariano MA. Synapse 20, 325-337 (1995).
32. 32. Koeltzow TE, Xu K Cooper DC, et al. J Neurosci 18, 2231-2238 (1998).